Biolinq Incorporated

Biolinq Incorporated develops continuous glucose monitoring systems for personal health management. The company's flagship product, Biolinq Shine™, is a needle-free, fully autonomous glucose sensor that measures and displays real-time glucose levels through an integrated color-changing LED light indicator (blue for target range, yellow for above-range glucose). The device integrates glucose monitoring with activity tracking and sleep monitoring via built-in accelerometer and ambient light sensors, eliminating the need for separate wearables. Biolinq Shine™ is FDA-cleared for use in persons 22 years or older not on insulin therapy and is intended to support glycemic control management through behavior and lifestyle modifications. The accompanying mobile application provides granular glucose analysis, correlates readings with meals, rest, and activity patterns, and delivers personalized insights to support trend tracking and health goal management. The device qualifies as a personal medical device for home and continuous use, targeting individuals managing non-insulin-dependent diabetes or pre-diabetes. Biolinq has secured substantial venture capital funding from prominent healthcare and investment firms, indicating commercial-stage development and market launch readiness.